FDA Drug Approvals for Migraine, Arthritis, and High Cholesterol, Coronavirus Updates, and More

Vyepti (eptinezumab) decreases monthly frequency of migraine days and can reduce symptoms for more immediate relief.

HEALTH NEWS ROUNDUP View Online

Questions on migraine? We've got you covered. Everyday Health will be attending the Migraine World Summit OnStage on March 11 to ask the world's leading experts in migraine all your questions. Submit yours today!

Top News Stories PAIN MANAGEMENT FDA Greenlights Vyepti, First IV Treatment to Prevent Migraine Attacks Vyepti (eptinezumab) decreases monthly frequency of migraine days and can reduce symptoms for more immediate relief. By Don Rauf | February 28, 2020 READ MORE

ARTHRITIS Arthritis Pain Gel Gets the Greenlight for Over-the-Counter Sale FDA approval of nonprescription Voltaren may expand access to the drug and save money. By Don Rauf | February 26, 2020 READ MORE

HEART HEALTH FDA Approves Non-Statin Drug to Treat High Cholesterol Nexletol also appears to reduce the risk of muscle pain, a common complaint of people on statins. By Becky Upham | February 25, 2020 READ MORE

INFECTIOUS DISEASES Coronavirus Outbreak Spreads to More Countries The first cases of probable community spread were reported in the United States and Germany. By Anna Brooks | February 27, 2020 READ MORE

DIGESTIVE HEALTH Better Sleep May Improve IBD Patient Lives Sleep quality is strongly associated with patients' mood state, disability, and overall living condition, a study finds. By Don Rauf | February 25, 2020 READ MORE

See All Of Our Great Newsletter Options! SIGN UP TODAY

You are receiving this email because you are signed up to receive emails from Everyday Health. You are registered with techandgio.cpex@blogger.com. Remove me from this list | Add me to this list | Manage my email settings | Customer Service Copyright © 2020 Everyday Health, Inc. All rights reserved. 345 Hudson Street, 16th Floor, New York, NY 10014 Subject to our terms of service and privacy policy